Quarterly ResultMay 6, 2026, 04:19 PM
Revolution Medicines Q1 Net Loss $(453.8)M; Raises $226.7M via ATM
AI Summary
Revolution Medicines reported a significant increase in net loss to $(453.8) million for Q1 2026, up from $(213.4) million in Q1 2025, primarily due to higher research and development and general and administrative expenses. To support its operations, the company raised $226.7 million in net proceeds through at-the-market equity offerings during the quarter, including initiating a new $1 billion ATM program. Despite an accumulated deficit of $3.3 billion, management expects existing capital to fund operations for at least 12 months.
Key Highlights
- Net loss increased to $(453.8) million in Q1 2026 from $(213.4) million in Q1 2025.
- Net loss per share was $(2.29) for Q1 2026, compared to $(1.13) in Q1 2025.
- Research and development expenses rose to $344.0 million from $205.7 million year-over-year.
- General and administrative expenses increased to $101.3 million from $35.0 million.
- Raised $226.7 million in net proceeds from at-the-market equity offerings in Q1 2026.
- Initiated a new $1.0 billion at-the-market equity offering program in February 2026.
- Cash, cash equivalents, and marketable securities totaled $1.91 billion as of March 31, 2026.
- Accumulated deficit reached $3.3 billion as of March 31, 2026.